Ono Pharmaceutical’s ONO-1110: A Promising Treatment for Postherpetic Neuralgia

ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.

Ono Pharmaceutical Co. Ltd is conducting a clinical study titled A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Postherpetic Neuralgia. The study aims to assess the efficacy and safety of ONO-1110, a drug intended to treat postherpetic neuralgia, a condition characterized by persistent nerve pain following shingles.

The intervention involves administering ONO-1110 tablets once daily to the experimental group, while a placebo is given to the control group. The primary goal is to determine the treatment’s effectiveness in alleviating pain associated with postherpetic neuralgia.

This interventional study employs a randomized, parallel assignment model with double masking, ensuring that both participants and investigators are unaware of group allocations. The primary purpose is treatment-focused, seeking to provide a new therapeutic option for patients.

The study began on November 24, 2024, with the latest update submitted on July 1, 2025. These dates are crucial as they indicate the study’s progression and ongoing recruitment status, which is currently active.

The successful development of ONO-1110 could significantly impact Ono Pharmaceutical’s market position, potentially boosting its stock performance and attracting investor interest. As the company advances in addressing postherpetic neuralgia, it may also influence competitive dynamics within the pharmaceutical industry.

The study is actively recruiting, with further details available on the ClinicalTrials portal.